<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02395224</url>
  </required_header>
  <id_info>
    <org_study_id>2013/1361</org_study_id>
    <nct_id>NCT02395224</nct_id>
  </id_info>
  <brief_title>A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-Norway</brief_title>
  <official_title>A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-Norway</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helse Midt-Norge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to provide original research results that may change clinical practice&#xD;
      related to metastatic colorectal cancer. The study will evaluate treatment and patient care&#xD;
      at different stages of the disease trajectory and the use of health care for this large group&#xD;
      of patients. It will be possible to compare the effectiveness of chemotherapy, radiotherapy&#xD;
      and symptomatic treatment given to &quot;real life&quot; patients with the efficacy reported in&#xD;
      randomised clinical trials. By using longitudinal information on imaging, biomarkers,&#xD;
      clinical staging and place of care it will be possible to improve patient classification at&#xD;
      various stages of the disease. Based on this, a more appropriate, individualized treatment&#xD;
      for colorectal cancer may be recommended during the phases of the disease trajectory.&#xD;
      Participation in this project will not influence the treatment for colorectal cancer. All&#xD;
      patients will be treated and followed-up according to current regional and national&#xD;
      guidelines.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The available evidence-based knowledge of patient management is translated into regularly&#xD;
      updated clinical guidelines for diagnosis, staging and treatment. The guidelines represent&#xD;
      the basis for oncology care in Norway, and health care providers are expected to follow these&#xD;
      guidelines. Current guidelines are derived from studies where patients are highly selected&#xD;
      and not representative for the whole cohort of patients with metastatic disease. One can&#xD;
      speculate if the results of trials conducted in regional centers can be generalized to whole&#xD;
      populations in a region. In this respect it will be valuable to study advanced colorectal&#xD;
      cancer in the whole population of Middle-Norway, with both one regional center and all other&#xD;
      hospitals in the area. More knowledge is needed for the optimal selection of treatment for&#xD;
      individual patients. In relation to symptom relief, physical and psychological functioning&#xD;
      and overall quality of life, there is clearly a lack of high quality research.&#xD;
&#xD;
      A longitudinal follow-up of a large number of metastatic colorectal cancer patients with&#xD;
      regular assessments has not been previously launched. The existing infrastructure in Norway&#xD;
      makes the study feasible and will provide high internal and external validity related to&#xD;
      clinical outcomes. The study will constitute a unique platform for comprehensive research&#xD;
      aimed at this patient group. It also provides a concept that can be transferred to other&#xD;
      major diseases, and it can be extended to other health regions of Norway.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>survival</measure>
    <time_frame>3 years or until death</time_frame>
    <description>Cancer-specific and overall survival according to treatment, age, sex, biological markers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>3 years or until death</time_frame>
    <description>reported on PG-SGA, patient version</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient expectations</measure>
    <time_frame>3 years or until death</time_frame>
    <description>patient expectations about effects of chemotherapy and satisfaction with treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO performance status</measure>
    <time_frame>3 years or until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of therapy</measure>
    <time_frame>3 years or until death</time_frame>
    <description>Number of dose reductions and treatment delays</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of therapy</measure>
    <time_frame>3 years or until death</time_frame>
    <description>Common Terminology Criteria for Adverse Events (CTCAE) v4.0; grade 3-4 for the following items: Hematology, infectious, gastrointestinal, neurological and thromboembolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>3 years or until death</time_frame>
    <description>reported on EORTC QLQ-C30</description>
  </secondary_outcome>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Neoplasms, Colorectal</condition>
  <condition>Neoplasm Metastasis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cancer treatment and follow-up according to current regional and national guidelines</intervention_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Newly diagnosis of metastatic colorectal cancer treated with a curative or non-curative&#xD;
        intention, or local disease not treated with a curative intention.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Colon or rectal cancer with synchronous metastases.&#xD;
&#xD;
          -  Colon or rectal cancer with metastatic relapse after curative primary treatment (for&#xD;
             localized disease or maximum one operation for distant metastases)&#xD;
&#xD;
          -  Localized colon or rectal cancer that due to tumor or patient related factors are not&#xD;
             treated with a curative intent&#xD;
&#xD;
          -  Written informed consent. In patients not able to consent due to cognitive impairment&#xD;
             consent can be by proxy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stein Kaasa, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Norwegian University of Science and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Are Korsnes Kristensen, md</last_name>
    <phone>+47 72825755</phone>
    <email>are.kristensen@ntnu.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kristiansund Hospital</name>
      <address>
        <city>Kristiansund</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ralph Herter, md</last_name>
      <email>Ralph.Herter@helse-mr.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Levanger Hospital</name>
      <address>
        <city>Levanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eivor Laugsand, md</last_name>
      <email>Eivor.Laugsand@helse-nordtrondelag.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Molde hospital</name>
      <address>
        <city>Molde</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabor H Liposits, md</last_name>
      <email>Gabor.Isivan.Liposits@helse-mr.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Namsos Hospital</name>
      <address>
        <city>Namsos</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hallvard Græslie, md</last_name>
      <email>Hallvard.Greslie@helse-nordtrondelag.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingunn Hatlevoll, MD</last_name>
      <phone>+47 72825678</phone>
      <email>Ingunn.Hatlevoll@stolav.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Volda Hospital HF</name>
      <address>
        <city>Volda</city>
        <zip>N-6100</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bottolf Lødemel, MD</last_name>
      <email>Bottolf.Lodemel@helse-mr.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ålesund Hospital</name>
      <address>
        <city>Ålesund</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hege Elvebakken, md</last_name>
      <email>Hege.Elvebakken@helse-mr.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 17, 2015</study_first_submitted>
  <study_first_submitted_qc>March 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2015</study_first_posted>
  <last_update_submitted>October 21, 2020</last_update_submitted>
  <last_update_submitted_qc>October 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Follow-up studies</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Palliative care</keyword>
  <keyword>Chemotherapy, adjuvant</keyword>
  <keyword>Cost-benefit analysis</keyword>
  <keyword>Population</keyword>
  <keyword>Antineoplastic agents/Adverse effects</keyword>
  <keyword>Terminal care</keyword>
  <keyword>Medical futility</keyword>
  <keyword>Survival rate</keyword>
  <keyword>Norway</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

